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We prospectively analysed a total of 21baby-mother pairs 
,with culture-proven Neisseria gonorrhoeae treated with a 
single low dose of ceftriaxone, namely 62.5 mg for babies 
and 125 mg for mothers respectively. · N. gonorrhoeae was 
eradicated from all babies' eyes with no residual damage, as 
well as from the mothers' cervixes, 
A single low dose of 62.5 mg ceftriaxone has emerged as 
the treatment of choice for• gonococcal ophthalmi(l 
neonatorum because of its excellent activity against 
N. gonorrhoeae, including penicillinase-producing strains. 
S Afr Med J 2002; 92: 2.38-24Q. 
Conjunctivitis is a common ocular inflammation involving all 
age groups and occurring worldwide. The incidence of acute 
conjunctivitis of the newborn has been reported to be high, 
occurring in about 12% of all newborns.1 Accurate figures for 
developing countries are not readily available but it is 
considered to be a common condition, with the majority of 
patients presenting to primary health care (PHC) facilities. 
Gonococcal ophthalmia neonatorum is a serious condition, 
which if left untreated can lead to blindness. It manifests in the 
newborn about 2 - 5 days after birth and produces an acute 
purulent discharge.' Single-dose therapy for gonococcal 
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ophthalmia neonatorum using ceftriaxone has been proposed 
previously at a single intramuscular (IM) dose of 125 mg.M The 
national programme for the syndromic management of 
sexually transmitted diseases (STDs) in South Africa' 
recommends the use of spectinomycin at 25 mg/kg IM for 
neonates and 2 g IM for mothers and their sexual partner I 
contact as first choice, while ceftriaxone is mentioned as an 
alternative at a single dose of 25 - 50 mg/kg IM for the neonate 
and 125 mg for the mother. 
This clinical study was undertaken to evaluate the single 
low-dose therapy at 62.5 mg IM in neonates diagnosed as 
having gonococcal ophthalmia while administering 125 mg IM 
to their mothers in order to eliminate cervical carriage. 
PATIENTS AND METHODS 
Neonates presenting to the eye clinic at King Edward VIII 
Hospital, Durban, with acute conjunctivitis were recruited for 
the study. Informed consent was obtained from the 
accompanying mothers. Babies' eyes were examined 
macroscopically by an ophthalmologist using ordinary light. 
Swab specimens were collected from all baby-mother pairs 
from the following sites: eyes of the baby, and urethra, cervix 
and rectum of the mother. Specimens were inoculated onto 
modified New York City medium' for the isolation of Neisseria 
gonorrhoeae and slide smears were made for direct 
immunofluorescence testing for Chlamydia trachomatis antigen 
(MicroTrak, Syva, UK).' 
N. gonorrhoeae isolates were confirmed on the basis of 
oxidase production and a positive glucose fermentation test. 
The strains were tested for penicillinase production (!}-
lactamase) and minimum inhibitory concentrations were 
determined for ceftriaxone using the agar dilution method. 
Auxo- and serotyping of all gonococcal isolates were 
performed according to previously described methods.'·' 
Ceftriaxone was administered to neonates at a single dose of 
62.5 mg IM and to the mothers at 125 mg IM. Mothers were 
provided with cotton wool balls and instructed by nursing staff 
to soak in tap water and wash off the purulent eye discharge of 
their babies as necessary. Follow-up swab specimens were 
collected from all the abovementioned sites 24 hours after 
treatment, and were processed as described for the isolation 
and detection of N. gonorrhoeae and C. trachomatis respectively. 
All neonates were hospitalised and observed for 48 hours 
before being discharged. The mothers were also hospitalised as 
boarder mothers. In baby-mother pairs where C. trachomatis 
antigens were detected, the neonates were given an oral 
suspension of erythromycin at 62.5 mg four times a day for 7 
days, while the mothers were treated with 500 mg 
erythromycin four times daily for 7 days. A follow-up clinic 
visit for both baby and mother was arranged for 7 days later. 





Discharge with severe lid swelling 
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Mild to moderate chemosis 
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Mode of delivery 
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Table II. 'fyping results and susceptibility profile of Neisseria 
gonorrhoeae isolates (N = 21) 
N 3 
Auxotype 
Proline-requiring 20 50 
Prototrophic 18 45 
Arginine- and proline-requiring 2 5 
Sero type 
A6 17 43 
AS 4 10 
Bl 2 5 
B3 3 8 
B4 7 16 
BS 4 10 
B22 3 8 
Penicillinase-producing strains 10 25 
Ceftriaxone MICs 
< 0.008 µg/ml . 39 98 
0.015 - O.D3 µg/ml 2 
MICs ~ minimal inhibitory concentrations. 
RESULTS 
A total of 21 baby-mother pairs were recruited. Patient data 
are presented in Table I. None of the neonates presented with 
ulceration of the cornea but in 3 there was severe chemosis. All 
babies were delivered vaginally and none of the mothers had 
had a caesarean section. Eye swabs from all neonates yielded 
N. gonorrhoeae and in 7 neonates (33%), C. trachomatis was also 
detected. N. gonorrhoeae was cultured from the genital sites of 
all mothers except one. C. trachomatis was detected in 
endocervical specimens of all mothers whose neonates had 
chlamydia! infection. A total of 40 gonococcal isolates were 
available for further characterisation and the data are shown in 
Table II. Praline-requiring and prototrophic strains were 
similar in number. The predominant serotype was A6 and the 
same auxotype and serotype were obtained from all 
baby-mother pairs. Penicillinase-producing strains accounted 
for 25% of all isolates and all isolates demonstrated very low 
minimal inhibitory concentrations (MICs) for ceftriaxone. 
The 24-hour follow-up specimens were all negative for N. 
gonorrhoeae. 
DISCUSSION 
The use of single-dose ceftriaxone for the treatment of 
gonococcal urethritis has been established in both local 
studies10 and those carried out elsewhere." However, what has 
been of significance has been the reduction in the dose 
administered - the 1989 Centers for Disease Control (CDC) 
guidelines for treatment of STDs recommended the use of a 
single 250 mg IM dose,12 while the 1993 and current 1998 
guidelines advocate a single dose of 125 mg IMI.13 This is not 
surprising in view of the fact that studies have shown efficacy 
in adults even at a dose of 62.5 mg.14 
In this study 21 baby-mother pairs were treated with single 
62.5 and 125 mg doses respectively. Efficacy was determined 
by doing a test of cure within 24 hours of therapy, with 
excellent results showing complete resolution of ocular 
inflammation and clearance of cervical carriage. This finding 
is not unexpected as uretheral clearance of N. gonorrhoeae in 
adult males has been achieved within 4 hours . 
While much work has been done on adult male gonococcal 
urethritis, there appears to be a lack of information on 
gonococcal ophthalmia neonatorum. The CDC guidelines13 
state that this condition should be managed with the same 
dose administered for adults. The findings of our study 
indicate that half the dose, namely 62.5 mg, effected 
elimination of the offending organism and resolution of 
symptoms within 24 hours, with no residual damage at 1-
week follow-up. 
The national programme for the syndromic management of 
STDs' proposes spectinomycin as first-choice treatment for 
gonococcal ophthalmia neonatorum, but this agent is not being 
used as it is not available at the majority of PHC facilities. The 
guidelines propose ceftriaxone as a second-line agent and do 
not recommend a specific dose, but indicate the use of 25 - 50 
mg/kg. Based on the clinical findings of this study together 
with the extremely low MIC values shown for gonococcal 
isolates, a 62.5 mg dose is appropriate and cost effective for the fJD 
management of gonococcal ophthalmia neonatorum. 
In 7 of the 21 neonates investigated, concurrent C. trachomatis 
infection was detected. With regard to neonatal conjunctivitis 
the national STD treatment protocols' advocate the additional 
prescription of erythromycin suspension for 7 days, and this is 
supported by the findings of this study. Five of the 21 neonates 
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were delivered at home and we could also not ascertain 
whether eye prophylaxis was administered to the remaining 
babies delivered at the clinics and hospitals. Hence, the impact 
of prophylaxis could not be measured. 
Characterisation of gonococcal isolates on the basis of 
nutritional requirements (auxotyping) showed the isolates to 
belong to two large groups, the wild prototrophic strains and 
those requiring proline for growth. Serotyping showed a 
predominance of strain A6, with the other strains 
demonstrating great diversity. There was matching for the 
isolates from neonates and mothers; however, for better 
epidemiological work the newer techniques of Opa typing 
might be more relevant. 15 
This study demonstrated good clinical efficacy with single 
low-dose ceftriaxone for the management of gonococcal 
ophthalmia neonatorum and elimination of cervical gonococcal 
infection from the infected mothers. The national STD 
treatment protocols' should recommend the use of a single 
62.5 mg dose for neonates and a dose of 125 mg IM for 
lactating and infected pregnant women. 
The authors thank the medical superintendent of King 
Edward VIII Hospital for permission to perform the study, and 
Dr C Groenewald for clinical examination of all patients. 
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higher compatible mouse. 
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